title: [Hereditary angioedema. A therapeutic guide].
abstract: Hereditary angioedema (HAE) is a rare autosomal dominant disease, characterized by episodes of edema involving the skin, gastrointestinal tract and larynx. HAE has a historical asphyxia mortality of 15% to 50%. It is the consequence of functional C1 inhibitor deficiency. The identification of bradykinin as the principal mediator of the disease has lead to the development of new drugs for its treatment. HAE management and treatment are agreed by international consensus decision. A therapeutic guide for the treatment of the disease is important to improve diagnosis and treatment. We here describe the pharmacology of drugs available for the treatment of HAE in Argentina: plasma derived C1 Inhibitor, the bradykinin antagonist: icatibant, the attenuated androgen danazol and the anti-fibrinolytic agents epsilonaminocaproic acid and tranexamic acid. Furthermore, we describe drug use and adverse effects control, as well as the last international consensus document recommendations applicable to Argentina to conform a first guide to HAE treatment in our country.
authors.affiliation: Servicio de Alergia e Inmunología, Hospital Británico de Buenos Aires, Argentina. amalbran31@hotmail.com
authors.forename: Alejandro
authors.initials: A
authors.lastname: Malbrán
authors.forename: Diego S
authors.initials: DS
authors.lastname: Fernández Romero
authors.forename: Alejandra
authors.initials: A
authors.lastname: Menéndez
mesh_terms: D000208:Acute Disease; D054179:Angioedemas, Hereditary / Q000628:therapy*; D001118:Argentina; D050718:Complement C1 Inhibitor Protein / Q000627:therapeutic use; D051056:Complement Inactivating Agents / Q000627:therapeutic use; D006801:Humans; D035583:Rare Diseases / Q000628:therapy*
chemical_list: D050718:Complement C1 Inhibitor Protein; D051056:Complement Inactivating Agents